That brand is more than just a logo - it’s your company’s reputation ... The company launched a new visual identity and a new brand purpose: to “unite science, talent and technology to ...

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $115.00.

Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of $115.00. Discover outperforming stocks and invest smarter ...

Zacks Research also issued estimates for Gilead Sciences’ Q4 2025 earnings at $1.86 EPS, FY2025 earnings at $7.12 EPS, Q3 2026 earnings at $2.19 EPS, Q4 2026 earnings at $2.03 EPS and FY2026 ...

Over the past 15 years, alternatives to the DSM have emerged. One is the Hierarchical Taxonomy of Psychopathology, or HiTOP. HiTOP is a grassroots project bringing together researchers from around ...

as blood cancer treatment Yescarta registered a 1% year-over-year drop in sales and its counterpart Tecartus gained just 2%. At the time, Gilead linked the stagnation to “increased in- and out ...

Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy. The litigation ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. Galapagos NV plans to split into two entities ...

(Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...